Advertisment

Amgen's Innovative Approach to Obesity Management: MariTide and the Future of Weight Loss Medications

author-image
Mason Walker
New Update
NULL

Amgen's Innovative Approach to Obesity Management: MariTide and the Future of Weight Loss Medications

Advertisment

A New Frontier in Obesity Management

Advertisment

Pharmaceutical giant Amgen is making strides in the battle against obesity with the development of their innovative weight-loss drug, MariTide. With promising early results indicating not only significant weight loss but also sustained effects even after dosage reduction, MariTide represents a potential game changer in long-term obesity management and related metabolic conditions.

MariTide: A Step Ahead in Weight Loss Medication

Already in the early stages of development, MariTide is showing considerable promise. Evidence has surfaced suggesting this drug could provide longer-lasting weight loss than its competitors, including popular obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The data from animal and early-stage human trials shows that MariTide promotes significant weight loss whilst maintaining an acceptable safety profile.

Advertisment

In a small, preliminary study, patients who received a monthly injection of MariTide lost up to 14.5% of their body weight in just 12 weeks. Remarkably, some participants were able to maintain this weight loss for up to 150 days after discontinuing the drug. This ability to sustain weight loss after cessation of treatment could be a key factor in MariTide's potential to revolutionize obesity treatment.

Understanding the Science Behind MariTide

MariTide, also known as AMG 133, works by combining the effects of an anti-GIPR monoclonal antibody and a GLP-1 receptor agonist. This combination has resulted in more pronounced weight loss than either agent alone in preclinical studies. The drug has also shown positive effects on metabolic markers, further solidifying its potential as a comprehensive solution for obesity management.

Advertisment

Comparison to Current Obesity Treatments

Currently, three GLP-1 injections, Wegovy, Zepbound, and Ozempic, are approved for obesity treatment in the US. These drugs mimic a hormone that reduces appetite and increases satiety. While they have been shown to be effective, helping patients lose about 15% to 21% of their body weight, patients often regain most of their lost weight after discontinuation of treatment. The high price of these drugs, coupled with limited insurance coverage, also poses a significant barrier to wider usage.

The Future of Obesity Treatment

Amgen's MariTide holds promise as a new approach to obesity treatment, offering longer-lasting weight loss and the flexibility to taper the dosage over time. The sustained effects of MariTide could make it a more effective and adaptable treatment for obesity and its associated health risks. The drug is currently in Phase 2 clinical trials, with results expected later this year.

More research is needed to confirm the efficacy and safety of MariTide. However, the initial data is promising, and the pursuit of this drug aligns with the growing demand for effective, long-term obesity treatments. With over 50 anti-obesity drugs currently in clinical trials, the future of obesity management is looking promising, and Amgen's MariTide is at the forefront of this exciting frontier.

Advertisment
Chat with Dr. Medriva !